Oncodesign Precision Medicine (ALOPM.PA)

Executive Summary

Oncodesign Precision Medicine (OPM) is a clinical-stage biopharmaceutical company leveraging its proprietary Nanocyclix® platform to develop novel small-molecule kinase inhibitors for cancer and neurodegenerative diseases. Based in Dijon, France, and publicly traded (ALOPM.PA), OPM focuses on addressing therapeutic resistance and metastasis through a patient-centric, translational approach. The company's lead asset, OPM-101, is a kinase inhibitor being evaluated in a Phase 1/2 trial for advanced melanoma (NCT07040436), which commenced enrollment in September 2025 and is expected to complete by December 2027. Additionally, OPM is expanding its pipeline into Parkinson's disease, reflecting the platform's broad applicability. With a market valuation of approximately €8.7 million, OPM represents an early-stage investment opportunity with significant upside potential if clinical data prove positive. Key upcoming milestones include initial efficacy and safety data from the OPM-101 trial, which could de-risk the platform and support further pipeline expansion. The company's focus on precision medicine and drug resistance positions it in a high-need therapeutic area, but success hinges on clinical validation and securing partnerships or funding for development.

Upcoming Catalysts (preview)

• H2 2026Interim data from Phase 1/2 trial of OPM-101 in advanced melanoma60% success